GlassScriptPhysician profile
John P Okerblom
NPI 1427046945
$15,755.83
in general payments reported to CMS, 2019-2025
56 companies · $1,741 in 2025
The $1,741 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,244 · 2020: $284 · 2021: $2,728 · 2022: $2,493 · 2023: $2,337 · 2024: $1,928 · 2025: $1,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,007.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,782.38 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $1,480.82 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,476.58 | 2020-2025 | |
| Lilly USA, LLC | $1,264.57 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,137.85 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,117.20 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $993.91 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $887.63 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $793.28 | 2019-2025 | Jardiance, Synjardy |
| Amarin Pharma, INC. | $602.49 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $517.67 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $387.50 | 2019-2024 | |
| Astellas Pharma US INC | $310.13 | 2019-2023 | Myrbetriq |
| Sanofi-Aventis U.S. LLC | $303.71 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $263.23 | 2019-2025 | Gardasil 9, Capvaxive |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Okerblom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.